All In Biotech

Drug Trial Radar · NCT04624659

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Jan 29, 2021

Primary completion

Feb 6, 2026

Study completion Mar 19, 2027

Sponsor

Lead sponsor
Forma Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
This study is currently undergoing a sponsor transition from Forma to Novo Nordisk. Sponsor field will be updated once the transition is complete.
First posted
Nov 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

Conditions

  • Sickle Cell Disease

Interventions

  • Etavopivat Tablets Low doseDrug

    200 mg once daily

  • Etavopivat Tablets High doseDrug

    400 mg once daily

  • Placebo TabletsDrug

    Placebo once daily

  • Etavopivat TabletsDrug

    Selected dose once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hemoglobin response rateTime frame: 24 Weeks
  2. Annualized vaso-occlusive crisisTime frame: 52 Weeks

Locations

142 sites in 17 countries. Site status is shown where the registry gives one.

  • Univ of Alabama Birmingham

    Birmingham, Alabama

  • Phoenix Children's Hsptl

    Phoenix, Arizona

  • [Legal] Woodland International Research Group, LLC

    Little Rock, Arkansas

  • [Legal] Collaborative Neuroscience Network, LLC

    Long Beach, California

  • Pacific Research Partners

    Oakland, California

  • UCSF Oakland Benioff ChildHosp

    Oakland, California

  • University Of California Irvine

    Orange, California

  • UC Davis Medical Center

    Sacramento, California

  • University of Connecticut

    Farmington, Connecticut

  • Yale University

    New Haven, Connecticut

  • Children's National Health Hospital

    Washington D.C., District of Columbia

  • Howard University

    Washington D.C., District of Columbia

  • Cornerstone Research Institute

    Altamonte Springs, Florida

  • University of Florida

    Gainesville, Florida

  • Foundation for Sickle Cell Disease Research

    Hollywood, Florida

  • University Of Miami

    Miami, Florida

  • Advanced Pharma CR

    Miami, Florida

  • Arnold Palmer Children's Hospital

    Orlando, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Sonar Clinical Research

    Atlanta, Georgia

  • Children's Healthcare of Atlanta Investigational Medication Pharmacy

    Atlanta, Georgia

  • Center for Blood Disorders Augusta University

    Augusta, Georgia

  • iResearch Atlanta, LLC

    Decatur, Georgia

  • University of Illinois at Chicago

    Chicago, Illinois

  • Children's Hosp-New Orleans

    New Orleans, Louisiana

  • University Of Maryland School of Medicine

    Baltimore, Maryland

  • Massachusetts General Hospital_Boston

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • [Legal] Dr. Vince Clinical Research, LLC and Dr. Vince Clinical Research, P.A.

    Detroit, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University School of Medicine_St. Louis

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • NYC Health+Hospitals

    Brooklyn, New York

  • Queens Hospital Center

    Jamaica, New York

  • North Shore Long Island Jewish Medical Center

    New Hyde Park, New York

  • Columbia University Medical Center_New York

    New York, New York

  • Weill Cornell Med Coll-NYPH

    New York, New York

  • Jacobi Medical Center

    The Bronx, New York

  • Montefiore Medical Center

    The Bronx, New York

  • [Legal] The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

Showing 40 of 142 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.